Email: info@apollotherapeutics.comTranslating innovative science into therapeutic potential

Latest Apollo Projects

Natriuretic receptor agonists for heart failure and cardiopulmonary fibrosis

By Richard Butt

Natriuretic receptor agonists for heart failure and cardiopulmonary fibrosis

a collaboration with Prof David Selwood and Prof Adrian Hobbs, University College London & Queen Mary University of London

Apollo is partnering with Prof David Selwood (Head of Biological and Medicinal Chemistry at the Wolfson Institute for Biomedical Research, University College London) and Prof Adrian Hobbs (Prof of Cardiovascular Pharmacology at the William Harvey Research Institute, Queen Mary University of London & Honorary Prof of Pharmacology, University College London) to develop small molecule modulators of natriuretic peptide receptors for treating cardiovascular disease. This 3-way collaboration stems from Prof Hobbs’ original research into natriuretic peptide receptors and the elucidation of new mechanistic insights into their role in cardioprotection. Building on Profs Selwood and Hobbs’ BHF translational award,  Apollo is now collaborating to develop a small molecule drug discovery programme that aims to deliver therapeutics that are effective in heart failure, myocardial infarction and pulmonary/cardiac fibrosis.


|